Profile data is unavailable for this security.
About the company
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-235.94m
- Incorporated2013
- Employees141.00
- LocationDyne Therapeutics Inc1560 Trapelo RoadWALTHAM 02451United StatesUSA
- Phone+1 (781) 786-8230
- Fax+1 (781) 786-8866
- Websitehttps://dyne-tx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Keros Therapeutics Inc | 151.00k | -152.99m | 1.99bn | 136.00 | -- | 5.29 | -- | 13,151.53 | -5.19 | -5.19 | 0.0051 | 10.43 | 0.0005 | -- | 2.11 | 1,110.29 | -45.21 | -35.95 | -48.12 | -38.07 | -- | -- | -101,319.20 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Amphastar Pharmaceuticals Inc | 644.40m | 137.55m | 2.00bn | 1.76k | 15.81 | 3.08 | 11.26 | 3.10 | 2.59 | 2.59 | 12.16 | 13.30 | 0.5716 | 2.78 | 6.33 | 365,925.60 | 12.38 | 9.42 | 14.42 | 11.56 | 54.91 | 47.83 | 21.65 | 15.23 | 1.70 | 10.68 | 0.4799 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Geron Corp | 237.00k | -184.13m | 2.05bn | 141.00 | -- | 7.69 | -- | 8,667.48 | -0.3246 | -0.3246 | 0.0004 | 0.455 | 0.0008 | -- | 0.0988 | 1,680.85 | -62.99 | -51.32 | -92.09 | -64.90 | -- | -- | -77,690.72 | -19,949.13 | -- | -- | 0.2484 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Intellia Therapeutics Inc | 36.28m | -481.19m | 2.07bn | 526.00 | -- | 1.91 | -- | 57.04 | -5.42 | -5.42 | 0.4106 | 11.29 | 0.0257 | -- | 1.80 | 68,963.88 | -34.11 | -31.34 | -37.31 | -34.53 | -- | -- | -1,326.51 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Guardant Health Inc | 563.95m | -479.45m | 2.11bn | 1.78k | -- | 13.29 | -- | 3.74 | -4.28 | -4.28 | 5.04 | 1.30 | 0.3321 | 4.00 | 6.06 | 317,002.80 | -28.23 | -22.26 | -31.99 | -24.59 | 59.74 | 64.62 | -85.02 | -97.07 | 6.24 | -12.04 | 0.8778 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -245.60m | 2.14bn | 268.00 | -- | 4.34 | -- | -- | -2.94 | -2.94 | 0.00 | 5.46 | 0.00 | -- | -- | 0.00 | -43.93 | -35.26 | -47.67 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0412 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Vera Therapeutics Inc | 0.00 | -95.99m | 2.15bn | 51.00 | -- | 17.28 | -- | -- | -2.28 | -2.28 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.54 | -- | -74.10 | -- | -- | -- | -- | -- | -- | -- | 0.3291 | -- | -- | -- | -7.79 | -- | -- | -- |
| Kymera Therapeutics Inc | 78.59m | -146.96m | 2.18bn | 187.00 | -- | 5.03 | -- | 27.77 | -2.52 | -2.52 | 1.35 | 7.11 | 0.1333 | -- | 7.38 | 420,278.10 | -24.93 | -23.03 | -28.76 | -27.64 | -- | -- | -186.99 | -207.82 | -- | -- | 0.0065 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Dyne Therapeutics Inc | 0.00 | -235.94m | 2.19bn | 141.00 | -- | 17.13 | -- | -- | -3.94 | -3.94 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -100.10 | -52.81 | -120.31 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| TG Therapeutics Inc | 233.66m | 12.67m | 2.20bn | 264.00 | 1,009.21 | 13.44 | 170.81 | 9.42 | 0.0141 | 0.0141 | 1.61 | 1.06 | 0.8933 | -- | 9.15 | 885,087.10 | 4.84 | -62.87 | 6.09 | -80.06 | 93.95 | -- | 5.42 | -405.03 | 5.18 | 1.64 | 0.3842 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Vericel Corp | 197.52m | -3.18m | 2.25bn | 314.00 | -- | 9.83 | 1,433.20 | 11.37 | -0.0684 | -0.0684 | 4.15 | 4.72 | 0.6304 | 4.26 | 3.77 | 629,031.90 | -1.02 | -3.07 | -1.17 | -3.50 | 68.64 | 67.87 | -1.61 | -4.49 | 4.21 | -- | 0.0004 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Denali Therapeutics Inc | 330.53m | -145.22m | 2.29bn | 445.00 | -- | 2.16 | -- | 6.94 | -1.09 | -1.09 | 2.39 | 7.45 | 0.2529 | -- | -- | 742,766.30 | -11.11 | -14.98 | -13.37 | -17.71 | -- | -- | -43.94 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Arvinas Inc | 78.50m | -367.30m | 2.32bn | 445.00 | -- | 3.50 | -- | 29.59 | -6.62 | -6.62 | 1.45 | 9.71 | 0.061 | -- | 157.00 | 176,404.50 | -28.35 | -22.01 | -36.10 | -26.47 | -- | -- | -464.71 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Avidity Biosciences Inc | 9.56m | -212.22m | 2.39bn | 253.00 | -- | 3.98 | -- | 249.68 | -2.90 | -2.90 | 0.131 | 6.32 | 0.0151 | -- | -- | 37,786.56 | -33.49 | -31.61 | -37.40 | -34.45 | -- | -- | -2,219.88 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Corcept Therapeutics Incorporated | 482.38m | 106.14m | 2.39bn | 352.00 | 24.10 | 4.69 | 22.28 | 4.95 | 0.9542 | 0.9542 | 4.32 | 4.90 | 0.8007 | 0.9374 | 13.37 | 1,370,384.00 | 17.62 | 21.17 | 20.65 | 23.85 | 98.66 | 98.52 | 22.00 | 27.23 | 4.31 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Merus NV | 43.95m | -154.94m | 2.40bn | 172.00 | -- | 6.62 | -- | 54.51 | -2.99 | -2.99 | 0.8519 | 6.16 | 0.1056 | -- | 13.56 | 255,505.80 | -37.24 | -29.35 | -45.30 | -35.36 | -- | -- | -352.56 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
Data as of Apr 23 2024. Currency figures normalised to Dyne Therapeutics Inc's reporting currency: US Dollar USD
34.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 25 Mar 2024 | 5.21m | 6.43% |
| Deep Track Capital LPas of 11 Jan 2024 | 4.50m | 5.55% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.34m | 4.11% |
| Citadel Advisors LLCas of 31 Dec 2023 | 3.05m | 3.77% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.34m | 2.88% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.26m | 2.79% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 2.01m | 2.48% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 1.90m | 2.34% |
| Logos Global Management LPas of 31 Dec 2023 | 1.88m | 2.32% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 1.22m | 1.50% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
